Form 8-K PURE BIOSCIENCE, INC. For: Nov 10

�

�

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

�

�

FORM 8-K

�

�

CURRENT REPORT

Pursuant to Section�13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November�10, 2014

�

�

PURE BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

�

�

�

Delaware	�	001-14468	�	33-0530289
(State or other jurisdiction of incorporation)	�	(Commission File Number)	�	(IRS Employer Identification No.)

�

1725 Gillespie Way El Cajon, California			�	92020
(Address of principal executive offices)			�	(Zip Code)

Registrant�s telephone number, including area code: (619)�596-8600

Not applicable

(Former name or former address, if changed since last report)

�

�

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

�

�	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

�

�	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

�

�	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

�

�	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

�

�

�

---

Item�8.01.

Other Items.

On November�10, 2014, PURE Bioscience, Inc (the �Company�) announced that it has withdrawn the Food Contact Notification (FCN) it submitted to the U.S. Food and Drug Administration (FDA) in July 2014 for the use of SDC in raw poultry processing. The Company decided to withdraw its FCN, without prejudice, following its receipt of a Deficiency Letter from the FDA stating that the agency has developed new data that calls into question the long established safety levels of the cumulative dietary intake of silver in the US resulting from the food contact uses the agency had previously approved. As a result, the FDA indicated that it would not approve the Company�s FCN absent new data or additional information that adequately addresses its new toxicity concerns.

The Company also announced that it would likely receive a similar Deficiency Letter from the FDA for the FCN it submitted in October 2014 for the use of SDC to reduce Salmonella, E. coli and Listeria in the processing of produce. If it does receive such a Deficiency Letter, the Company announced that it intends to similarly withdraw that FCN until it can provide the FDA with the additional data and information necessary to address the FDA�s concerns.

A copy of the Company�s press release is filed herewith as Exhibit 99.1, and is incorporated herein by reference.

�

Item�9.01.

Financial Statements and Exhibits.

(d) Exhibits

�

99.1	��	Press Release, dated November�10, 2014.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

�

	�		�	PURE BIOSCIENCE, INC.
Dated: November�10, 2014	�		�	By:	�	/s/ Henry R. Lambert
	�		�		�	Henry R. Lambert
	�		�		�	Chief Executive Officer

---

EXHIBIT INDEX

�

Exhibit Number	��	Description
99.1	��	Press Release, dated November�10, 2014.

Exhibit 99.1

�

PURE WITHDRAWS FOOD CONTACT NOTIFICATION FOR SDC

ANTIMICROBIAL USE IN RAW POULTRY PROCESSING

� Use of EPA Approved PURE^� Hard Surface Disinfectant

Not Effected By FDA Review �

SAN DIEGO, Calif., (November 10, 2014) � PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that it has withdrawn the Food Contact Notification (FCN) it submitted to the U.S. Food and Drug Administration (FDA) in July 2014 for the use of SDC in raw poultry processing.�PURE had submitted the FCN based on test results demonstrating that the SDC use provided a material significant reduction in Salmonella contamination in raw poultry.

The Company decided to withdraw its FCN, without prejudice, following its receipt of a Deficiency Letter from the FDA stating that the agency has developed new data that is currently under review. That data calls into question the long established safety levels of the cumulative dietary intake of silver in the US resulting from the food contact uses the agency had previously approved.�As a result, the FDA indicated that it would not approve PURE�s FCN absent new data or additional information that adequately addresses its new toxicity concerns. The FDA has not yet publically released this new data.

Going forward, the Company intends to work with the FDA and the food processing industry to collect or develop the additional data and information necessary to address the FDA�s current safety concerns. The Company cannot provide an exact timeline of when it will be able to resubmit an FCN for the use of SDC as a direct food contact processing aid for treating raw poultry.

PURE had previously announced that it had submitted an FCN on October�8, 2014 for the use of SDC to reduce Salmonella, E. coli and Listeria in the processing of produce. Because the FDA is unlikely to approve any new uses of silver in food processing at this time, PURE anticipates that it will receive a similar Deficiency Letter from the FDA regarding the use of SDC in the processing of produce. If the Company does receive such a notification, it intends to similarly withdraw that FCN until it can provide the FDA with the additional data and information necessary to address the FDA�s concerns.

� Continued �

---

Hank R. Lambert, CEO of PURE said, �We are surprised and deeply disappointed in the need to withdraw our FCN and to delay our commercialization efforts into this new market for SDC. However, going forward we intend to work with the FDA and members of the food processing industry to address the FDA�s request for additional data regarding exposure levels and the use of silver in food processing. Our confidence in SDC is not diminished. Given what we have learned from our earlier test results demonstrating SDC�s ability to significantly reduce or eliminate pathogen levels in poultry and produce, our dedication does not waiver to drive SDC as a unique food safety solution into the food processing market.� Lambert continued, �While we gather this data, we are continuing to aggressively commercialize our EPA registered PURE^� Hard Surface disinfectant for use in the food service and food processing industries.�

About PURE Bioscience, Inc.

PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena � providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

Forward-looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company�s cash position and liquidity requirements; the Company�s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company�s current and future products and services in the marketplace, including acceptance of the Company�s PURE^� Hard Surface disinfectant by SUBWAY^� franchisees; the ability of the Company to develop effective new products and receive regulatory approvals of such products; competitive factors; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company�s periodic report filings with the Securities and Exchange Commission, including our annual report on Form 10-K filed October�28, 2014. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

�

Company Contact:	��		��
Peter C. Wulff, CFO�& COO	��	Terri MacInnis, VP of IR	��	Tom Hemingway
PURE Bioscience, Inc.	��	Bibicoff + MacInnis, Inc.	��	Redwood Investment Group
619-596-8600 ext.111	��	818-379-8500	��	714-978-4425
[email protected]	��	[email protected]	��	[email protected]

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Central 1 announces results from 2024 Annual General Meeting
• USB Batteryless System Logger from Amfeltec’s PocketShark Family is in Production
• Tambourine Room by Tristan Brandt at Carillon Miami Wellness Resort Honored With Michelin Star for 2024